Log in

ASX:IPDImpedimed Stock Price, Forecast & News

A$0.04
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.04
Now: A$0.04
A$0.04
50-Day Range
A$0.04
MA: A$0.04
A$0.04
52-Week Range
A$0.03
Now: A$0.04
A$0.23
Volume1.62 million shs
Average VolumeN/A
Market Capitalization$40.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance instruments, consumables, and software in Australia, North America, and internationally. The company operates through Medical and Test & Measurement segments. It offers SOZO, a next generation bioimpedance spectroscopy digital health platform; and L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb. The company also provides SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. In addition, the company supplies power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 7 3860 3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.19 million
Cash FlowA$0.03 per share
Book ValueA$0.04 per share

Profitability

Miscellaneous

Employees68
Outstanding Shares1,001,699,968
Market Cap$40.07 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IPD News and Ratings via Email

Sign-up to receive the latest news and ratings for IPD and its competitors with MarketBeat's FREE daily newsletter.

Impedimed (ASX:IPD) Frequently Asked Questions

How has Impedimed's stock been impacted by COVID-19 (Coronavirus)?

Impedimed's stock was trading at A$0.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPD stock has decreased by 47.4% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus.

Has Impedimed been receiving favorable news coverage?

News stories about IPD stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Impedimed earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Impedimed.

Who are some of Impedimed's key competitors?

What other stocks do shareholders of Impedimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Impedimed investors own include Bardoc Gold (BDC) and Appen (APX).

Who are Impedimed's key executives?

Impedimed's management team includes the following people:
  • Mr. Richard Carreon, MD, CEO, Pres & Exec. Director
  • Mr. Morten Vigeland, Chief Financial Officer
  • Mr. David Michae Adams J.D., BSc, Sr. VP of Ventures, Licensing & Corp. Devel.
  • Mr. Dennis Schlaht, Sr. VP of R&D and Technology
  • Ms. Catherine Kingsford, Sr. VP of Medical Affairs

What is Impedimed's stock symbol?

Impedimed trades on the ASX under the ticker symbol "IPD."

What is Impedimed's stock price today?

One share of IPD stock can currently be purchased for approximately A$0.04.

How big of a company is Impedimed?

Impedimed has a market capitalization of $40.07 million and generates $5.19 million in revenue each year. Impedimed employs 68 workers across the globe.

What is Impedimed's official website?

The official website for Impedimed is www.impedimed.com.

How can I contact Impedimed?

The company can be reached via phone at 61 7 3860 3700.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.